Encaleret

Phase 2Small molecule

CCalcilytix Therapeutics, Inc., a BridgeBio company

Encaleret is one of 10 small molecule programs targeting Hypocalcemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypocalcemiaActive, not recruiting

HypocalcemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Hypocalcemia

#DrugCompanyPhaseTrials

Calciferol

Alnylam Pharmaceuticals

Zemplar

Forteo

2 4

Rocaltrol

Alnylam Pharmaceuticals

Phase 2

1 5

Calcium

Eli Lilly

Phase 2

1 6

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Phase 1

1 7

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

1 8

Encaleret

CCalcilytix Therapeutics, Inc., a BridgeBio company

Phase 2

2 9

Tums

Calcium Supplement

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Active, not recruiting

Efficacy and Safety

NCT05680818

Q4 2030

Phase 2/3Recruiting

Hypocalcemia

NCT07080385

Clinical

Trials by Indication[1]

Hypocalcemia2 trials

Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Recruiting·CCalcilytix Therapeutics, Inc., a BridgeBio company·Phase 2/3·NCT07080385·28 enrolled

Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

Completed·CCalcilytix Therapeutics, Inc., a BridgeBio company·Phase 2·NCT04581629·13 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

Active, not recruiting·CCalcilytix Therapeutics, Inc., a BridgeBio company·Phase 3·NCT05680818·67 enrolled

Unspecified1 trial

PTH-independent Effects of Encaleret

Completed·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT05735015·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Encaleret. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Encaleret compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Encaleret. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Calcilytix Therapeutics, Inc., a BridgeBio company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCalcilytix Therapeutics, Inc., a BridgeBio company

Encaleret

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Q4 2030

Trials by Indication[1]

Hypocalcemia2 trials

Efficacy and Safety1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News